| Followers | 37 |
| Posts | 15255 |
| Boards Moderated | 0 |
| Alias Born | 08/29/2012 |
Saturday, October 12, 2024 8:46:37 PM
1. You completely forgot Tylenol with Codeine which just launched on Monday. IQVIA is $47 Million.
2. Use 1% market capture for Vigabatrin. We don't own the product. We are the contract manufacturer.
Both jour_trader and WeeZuhl are full of SH*T when they say it will bring in zero revenue when it has ALREADY brought in revenue from the launch and is STILL on the market as evidenced below:
Launch Revenue:
https://www.businesswire.com/news/home/20240401540349/en/Pyros-Pharmaceuticals-Announces-VIGPODER%E2%84%A2-vigabatrin-is-Now-Available
Still On Market Revenue:
https://pyrostotalcare.com/
3. Cut Vyvanse IQVIA in half to be on the safe side due to generic entry.
4. The IQVIA for Percocet, Norco, and Methadone are outdated but it's the latest publicly available info we have. As stated by Nasrat, we will get an up-to-date IQVIA when these products launch.
2. Use 1% market capture for Vigabatrin. We don't own the product. We are the contract manufacturer.
Both jour_trader and WeeZuhl are full of SH*T when they say it will bring in zero revenue when it has ALREADY brought in revenue from the launch and is STILL on the market as evidenced below:
Launch Revenue:
https://www.businesswire.com/news/home/20240401540349/en/Pyros-Pharmaceuticals-Announces-VIGPODER%E2%84%A2-vigabatrin-is-Now-Available
Still On Market Revenue:
https://pyrostotalcare.com/
3. Cut Vyvanse IQVIA in half to be on the safe side due to generic entry.
4. The IQVIA for Percocet, Norco, and Methadone are outdated but it's the latest publicly available info we have. As stated by Nasrat, we will get an up-to-date IQVIA when these products launch.
MAKE ELITE GREAT AGAIN!
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
